• Profit after tax of $4.94 million, up 199% from prior period
• Fair value gain of $5.34 million on investments
• BTC Cardio secures exclusive distribution deal with Corcym Srl
• Continued progress across investee companies

BTC Health Ltd, a Pooled Development Fund investing in the healthcare sector, has reported a strong financial performance for the half-year ended 31 December 2024. The company recorded a profit after tax of $4.94 million, up 199% from the prior period's $1.65 million. This was driven by a fair value gain of $5.34 million on the company's investments, which include its wholly-owned subsidiaries BTC Specialty Health, BTC Pharma, and BTC Cardio. BTC Specialty Health, the company's medical device distribution business, saw revenue decline to $2.6 million due to the discontinuation of the ambIT infusion pumps. However, the successful inclusion of the Elasto-Q and Micrel pain infusion pumps on the Prescribed List of Medical Devices in November 2024 is expected to drive growth in the second half of the financial year.BTC Pharma, which licenses and distributes specialized pharmaceutical products, reported a 10% increase in revenue from its Bronchitol and Aridol respiratory products to $0.64 million.The standout performer was BTC Cardio, which entered an exclusive partnership with the multinational group Corcym Srl in December 2024. Under this agreement, BTC Cardio has assumed responsibility for Corcym's established heart valve business in Australia and New Zealand, effective 1 January 2025. This transaction, along with the growing ECMO product range, contributed to the significant increase in BTC Cardio's valuation to $3.74 million.The company's cash balance decreased to $794,679 during the period, primarily due to a $890,000 loan to BTC Cardio to support its working capital requirements. BTC Health continues to assess new investment opportunities to further diversify its portfolio in the healthcare sector.

BTC Health Ltd expects continued growth and progress across its investee companies in the second half of the 2025 financial year. The company anticipates revenue and profit contributions from the new Corcym heart valve distribution agreement and the successful inclusion of the Elasto-Q and Micrel pain infusion pumps on the Prescribed List of Medical Devices.

BTC Health Ltd remains focused on identifying and investing in high-quality healthcare companies that can deliver sustainable growth and returns for shareholders. The company will continue to support the strategic initiatives of its existing investee companies while actively seeking new investment opportunities to further diversify its portfolio and drive long-term value creation.